EGFR and non-small cell lung carcinoma: This led to FDA and EMA approvals of osimertinib as first-line therapy for locally advanced or metastatic NSCLC with EGFR exon-19 deletions or exon-20 or -21 mutations (detected by an approved companion diagnostic test).